Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
Table 4
Adjusted odds ratios (OR) of clinical parameters included for most accurate designation of subjects discontinuing treatment due to pulmonary adverse effects.